Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	116882
Country	China

Category	Oncology
Manuscript Type	Review
Article Title	Advancing human epidermal growth factor receptor 2-positive gastric cancer therapy: Toward targeted immunotherapy and antibody-drug conjugates
Manuscript Source	Invited Manuscript
All Author List	Jia-Ju Xu, Chun-Xiao Ni, Ping Wang, Li-Dong Qin and Jia-Ju Xu
Funding Agency and Grant Number	Funding Agency Grant Number Scientific Research Fund of Tai’an Science and Technology Agency No. 2019NS180
Corresponding Author	Jia-Ju Xu, MD, Department of Medical Oncology, Tai’an City Central Hospital, No. 29 Longtan Road, Tai’an 271000, Shandong Province, China. jiajuxu1101@163.com
Key Words	Human epidermal growth factor receptor 2-positive gastric cancer; Drug resistance mechanisms; Antibody-drug conjugates; Immunotherapy; Precision medicine; Liquid biopsy; Multi-omics analysis
Core Tip	The therapeutic landscape for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is undergoing a paradigm shift, moving beyond traditional HER2 inhibition. This transformation is fueled by two key developments: First, the advent of potent antibody-drug conjugates (trastuzumab deruxtecan and disitamab vedotin) that deliver cytotoxic payloads with high precision; Second, the success of combined modality therapies that synergistically target HER2, immune checkpoints, and chemotherapy. Our review offers a critical analysis of these strategies, deciphers the complex molecular basis of resistance, and conceptualizes a next-generation precision oncology framework integrating real-time monitoring via liquid biopsy and artificial intelligence-driven analytics to outmaneuver tumor evolution.
Citation	Xu JJ, Ni CX, Wang P, Qin LD, Xu JJ. Advancing human epidermal growth factor receptor 2-positive gastric cancer therapy: Toward targeted immunotherapy and antibody-drug conjugates. World J Gastrointest Oncol 2026; In press

Received	2025-11-24 01:49
Peer-Review Started	2025-11-24 01:49
First Decision by Editorial Office Director	2026-01-07 09:21
Return for Revision	2026-01-07 10:19
Revised	2026-01-15 10:04
Publication Fee Transferred
Second Decision by Editor	2026-02-10 02:48
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-02-10 07:28
Articles in Press	2026-02-10 07:28
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com